Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-314 (Nafabelltan) in COVID-19 Pneumonia
NCT04628143Phase 2Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Dec 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Nafamostat + SOC with Standard of Care (2 arms). Primary endpoint: Time to clinical improvement at 28 days. Started Dec 2020; status: completed.
02
Drugs
Nafabelltan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04628143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04628143.